Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma × Adjuvants, Pharmaceutic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Dysplasia 1 Squamous Intraepithelial Lesions 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Papillomavirus Infections 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Liver Diseases 1 Liposarcoma 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Trabectedin 5 Doxorubicin 5 pazopanib 3 Radiotherapy 3 Gemcitabine 3 ribociclib 2 pembrolizumab 2 palbociclib 2 brostallicin 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Imatinib Mesylate 2 Docetaxel 2 Dexamethasone 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 tanespimycin 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 sitravatinib 1 saracatinib 1 romidepsin 1 ridaforolimus 1 regorafenib 1 plitidepsin 1 perifosine 1 olaparib 1 liposomal doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡